EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe.

The European Breast Cancer Council (EBCC) traditionally identifies controversies or major deficiencies in the management of patients with breast cancer and selects a multidisciplinary expert team to collaborate in setting crucial principles and recommendations to improve breast cancer care. The 2024 EBCC manifesto focuses on disparities in the care of patients with metastatic breast cancer. There are several reasons for existing disparities both between and within countries. Our recommendations aim to address the stigma of metastatic disease, which has led to significant disparities in access to innovative care regardless of the gross national income of a country. These recommendations are for different stakeholders to promote the care of patients with metastatic breast cancer across Europe and worldwide.

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest MI reports speaker fees/honoraria from Novartis, Seattle Genetics, Daichi, Menarini/Stemline and Gilead, research grants (to institution) from Pfizer, Roche, Inivata Inc, Natera Inc and Gilead, and meeting/travel grants from Roche, AstraZeneca and Gilead (all outside the submitted work). TS reports personal fees for advisory board participation from MSD and Roche and for invited speaker engagements at regional conferences from Roche and Pfizer (outside the submitted work). EB reports honoraria from Pfizer, Lilly and Incyte, consulting/advisory roles for Pfizer, Sandoz-Novartis, Daiichi Sankyo/AstraZeneca and Menarini, and travel/accommodation/expenses from Pfizer and Novartis. DL reports payment (to institution) from the European Medicines Agency for board participation and payment (to institution) from the ESMO Sarcoma and Rare Cancers meeting for participation as a guest speaker. GSS reports institutional research support from Agendia, AstraZeneca, Merck, Novartis, Roche and Seagen. He is a board member of the Dutch Medicines Evaluation Board. AV-S reports speaker honoraria from Ibex Medical Analytics, Myriad, AstraZeneca, Roche and MSD, advisory board participation for Ibex Medical Analytics and Primaa, travel support from Ibex Medical Analytics and AstraZeneca, research grants from Ibex Medical Analytics, Owkin, Primaa, AstraZeneca and MSD Avenir, and stock options for Ibex Medical Analytics. IM declares small fees as honoraria for advisory boards supported by Eli Lilly, Novartis, Pfizer, SeaGen, Daiichi Sankyo, AstraZeneca, Gilead, and Menarini Stemline. PA reports honoraria from Synthon, Roche and Gilead, consulting or advisory roles for MacroGenics, Boehringer Ingelheim, Novartis, amcure, Roche, Novartis, Amgen, Servier, G1 Therapeutics, Radius Health, Deloitte, Menarini, Gilead Sciences, Incyte and Lilly, research funding from Roche (to institution) and travel/accommodation/expenses from Amgen, MSD Oncology, Roche Belgium, Pfizer, Daiichi Sankyo/AstraZeneca and Gilead Sciences. FC reports consultancy roles for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, IQVIA, MacroGenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva and TouchIME. VPR reports no conflict of interest related to the current article and reports grants from Agendia BV more than 5 years ago. DC reports non-personal relationships (any fees go to employer) with AstraZeneca, Eisai, Seagen, Roche, Pfizer, Lilly, Novartis, Synthon, GSK, Gilead, Daichi and Menarini/Stemline; he is Chair of the Board of the non-profit “Make 2nds Count” charity and the Breast International Group. FP, FVD, OK-P and FL report no conflicts of interest.